You are viewing the site in preview mode

Skip to main content

Advertisement

Table 7 Studies of stereotactic body radiotherapy for stage I NSCLC in the elderly

From: Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer

Author Age (range) n T stage Doses Local control Overall survival
Haasbeek CJ et al. [9] ≥ 75 (75–91) 193 T1 118 60 Gy/3 fr 89% at 3 years 45% at 3 years
    T2 85 60 Gy/5 fr   
     60 Gy/8 fr   
Takeda A et al. [12] ≥ 80 (80–91) 109 T1a 32 50 Gy/4 fr 82.3% at 3 years 53.7% at 3 years
    T1b 35 40 Gy/ 5 fr   
    T2 42    
Sandhu AP et al. [11] ≥ 80 (80–89) 24 T1 18 48 Gy/4 fr 100% 74% at 2 years
    T2a 6 56 Gy/5 fr (4.3–61.2 months)  
This study ≥ 85 (85–93) 20 T1a 9 48 Gy/4 fr 83.1% at 3 years 71.2% at 2 years
(Hayashi S et al.)    T1b 7 60 Gy/10 fr   40.7% at 3 years
    T2a 4